Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
暂无分享,去创建一个
P. Merlet | L. Vercellino | B. Hosten | L. Dercle | M. Salvatore | K. Capaccione | A. Moya-Plana | B. Baroudjian | Aileen Deng | R. Yeh | J. Das | Dorine de Jong | B. Braumuller | Camry A’Keen | A. Moya‐Plana
[1] A. Lallas,et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.
[2] T. Sarna,et al. Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship , 2022, Frontiers in Oncology.
[3] R. Hicks,et al. PET/CT variants and pitfalls in malignant melanoma , 2022, Cancer Imaging.
[4] Hubing Wu,et al. [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04 , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[5] U. Reineke,et al. Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286 , 2021, Poster Presentations - Late-Breaking Proffered Abstracts.
[6] S. Aerts,et al. Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value , 2021, Frontiers in Oncology.
[7] E. Lopci. Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer , 2021, Journal of clinical medicine.
[8] W. Hayes,et al. Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic , 2021, Frontiers in Oncology.
[9] D. Jäger,et al. FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[10] M. Pomper,et al. First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients , 2021, The Journal of Nuclear Medicine.
[11] L. Schwartz,et al. Don't overlook spleen glucose metabolism on [18F]-FDG PET/CT for cancer drug discovery and development. , 2021, Current cancer drug targets.
[12] E. Moscarella,et al. Usefulness of High-Frequency Ultrasonography in the Diagnosis of Melanoma: Mini Review , 2021, Frontiers in Oncology.
[13] Hsin-Ell Wang,et al. Development of Radiofluorinated Nicotinamide/Picolinamide Derivatives as Diagnostic Probes for the Detection of Melanoma , 2021, International journal of molecular sciences.
[14] Xue-juan Wang,et al. Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT , 2021, The Journal of Nuclear Medicine.
[15] L. Vercellino,et al. Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy , 2021, Frontiers in Oncology.
[16] M. Egger. The Role of Clinical Prediction Tools to Risk Stratify Patients with Melanoma After a Positive Sentinel Lymph Node Biopsy , 2021, Annals of Surgical Oncology.
[17] J. Nosanchuk,et al. Fungal Melanin and the Mammalian Immune System , 2021, Journal of fungi.
[18] M. Pomper,et al. Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. , 2021, Journal of medicinal chemistry.
[19] Dale Han,et al. Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma , 2021, Current Treatment Options in Oncology.
[20] Xiangxi Meng,et al. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab , 2021, Clinical nuclear medicine.
[21] N. Aide,et al. Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[22] L. Qiu,et al. Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers , 2021, Cancer Immunology, Immunotherapy.
[23] F. Facchiano,et al. Nicotinamide inhibits melanoma in vitro and in vivo , 2020, Journal of experimental & clinical cancer research : CR.
[24] M. Moncrieff,et al. Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management , 2020, Annals of Surgical Oncology.
[25] Hsin-Ell Wang,et al. Evaluation of Radioiodinated Fluoronicotinamide/Fluoropicolinamide-Benzamide Derivatives as Theranostic Agents for Melanoma , 2020, International journal of molecular sciences.
[26] Jinming Yu,et al. 18F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer , 2020, Translational lung cancer research.
[27] Evan P. Stater,et al. Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring , 2020, The Journal of Nuclear Medicine.
[28] Hyung-Seok Kim,et al. Ultrasensitive detection of malignant melanoma using PET molecular imaging probes , 2020, Proceedings of the National Academy of Sciences.
[29] S. de Jong,et al. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192 , 2020, The Journal of Nuclear Medicine.
[30] L. Schwartz,et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4 , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[31] G. Argenziano,et al. A preliminary study for quantitative assessment with HFUS (High Frequency ultrasound) of nodular skin melanoma Breslow thickness in adults before surgery: Interdisciplinary team experience. , 2020, Current radiopharmaceuticals.
[32] J. Klubo-Gwiezdzinska,et al. Targeting Integrins with Radiolabeled RGD Analogs for Radiotheranostics of Metastatic Radioactive Iodine Non-Responsive Thyroid Cancer - New Avenues in Personalized Medicine. , 2020, Thyroid : official journal of the American Thyroid Association.
[33] C. H. Nielsen,et al. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[34] G. Calais,et al. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. , 2019, European journal of cancer.
[35] L. Vercellino,et al. Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab , 2019, The Journal of Nuclear Medicine.
[36] C. Lebbé,et al. Severe Gastrointestinal Toxicity of MEK Inhibitors. , 2019, Melanoma research.
[37] E. Jones,et al. 68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. , 2019, Radiology. Imaging cancer.
[38] L. Schwartz,et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[39] Xiaoling Hu,et al. 89Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating In Vivo PD-L1 Levels in Melanoma Mouse Model. , 2019, Cancer biotherapy & radiopharmaceuticals.
[40] S. Swetter,et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[41] R. Turner,et al. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma , 2019, Annals of Surgical Oncology.
[42] R. Houot,et al. Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[43] R. Boellaard,et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer , 2018, Nature Communications.
[44] Ronald Boellaard,et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer , 2018, Nature Medicine.
[45] Thomas Lindner,et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.
[46] C. Balleyguier,et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. , 2018, European journal of cancer.
[47] Xiaohu Zhao,et al. Biodistribution, Radiation Dosimetry, and Clinical Application of a Melanin-Targeted PET Probe, 18F-P3BZA, in Patients , 2018, The Journal of Nuclear Medicine.
[48] D. Schadendorf,et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.
[49] J. Talbot,et al. Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma , 2018, Oncotarget.
[50] A. Casadevall,et al. Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy , 2018, Scientific Reports.
[51] A. Mackiewicz,et al. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients , 2018, Contemporary oncology.
[52] R. Houot,et al. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. , 2018, European journal of cancer.
[53] Lawrence H. Schwartz,et al. (18)F-FDG PET and CT-scan Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-PD1 Immune Checkpoint Inhibitor , 2018 .
[54] C. Craik,et al. Imaging PD-L1 Expression with ImmunoPET , 2017, Bioconjugate chemistry.
[55] D. Schadendorf,et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.
[56] L. Mansi,et al. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[57] J. Utikal,et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. , 2017, European journal of cancer.
[58] Yingying Zhang,et al. Detection of melanoma metastases with PET-Comparison of 18F-5-FPN with 18F-FDG. , 2017, Nuclear medicine and biology.
[59] P. Garg,et al. 4-11C-Methoxy N-(2-Diethylaminoethyl) Benzamide: A Novel Probe to Selectively Target Melanoma , 2017, The Journal of Nuclear Medicine.
[60] D. Rigel,et al. Analysis of Trends in US Melanoma Incidence and Mortality , 2017, JAMA dermatology.
[61] N. Moins,et al. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy1 , 2016, Neoplasia.
[62] P. Merlet,et al. [18F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to 18F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases. , 2016, Nuclear medicine and biology.
[63] D. Colin,et al. Preclinical validations of [18F]FPyPEGCBT-c(RGDfK): a 18F-labelled RGD peptide prepared by ligation of 2-cyanobenzothiazole and 1,2-aminothiol to image angiogenesis , 2016, EJNMMI Radiopharmacy and Chemistry.
[64] Hsin-Ell Wang,et al. Preparation and characterization of a novel Al(18)F-NOTA-BZA conjugate for melanin-targeted imaging of malignant melanoma. , 2016, Bioorganic & medicinal chemistry letters.
[65] Wojciech G. Lesniak,et al. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. , 2016, Bioconjugate chemistry.
[66] M. Askarian-Amiri,et al. Signaling Pathways in Melanogenesis , 2016, International journal of molecular sciences.
[67] Z. Rzepka,et al. From tyrosine to melanin: Signaling pathways and factors regulating melanogenesis. , 2016, Postepy higieny i medycyny doswiadczalnej.
[68] A. Brożyna,et al. Melanin content in melanoma metastases affects the outcome of radiotherapy , 2016, Oncotarget.
[69] A. Ribas,et al. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy , 2016, Therapeutic advances in medical oncology.
[70] P. Rutkowski,et al. Trametinib: a MEK inhibitor for management of metastatic melanoma , 2015, OncoTargets and therapy.
[71] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[72] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[73] Hsin-Ell Wang,et al. Synthesis and evaluation of ¹²³/¹³¹I-Iochlonicotinamide as a novel SPECT probe for malignant melanoma. , 2015, Bioorganic & medicinal chemistry.
[74] D. Colin,et al. A novel 2-cyanobenzothiazole-based (18)F prosthetic group for conjugation to 1,2-aminothiol-bearing targeting vectors. , 2015, Organic & biomolecular chemistry.
[75] K. Pitman,et al. [99mTc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial , 2015, Annals of Surgical Oncology.
[76] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] O. Prante,et al. PET Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments , 2014, BioMed research international.
[78] A. Lambeir,et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). , 2014, Journal of medicinal chemistry.
[79] R. Elashoff,et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.
[80] A. Brożyna,et al. Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. , 2013, Human pathology.
[81] F. Penault-Llorca,et al. In vivo efficacy of melanoma internal radionuclide therapy with a 131I‐labelled melanin‐targeting heteroarylcarboxamide molecule , 2013, International journal of cancer.
[82] S. O'toole,et al. BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.
[83] A. Casadevall,et al. Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma , 2013, Journal of skin cancer.
[84] S. Gottschalk,et al. Cancer-associated fibroblasts as targets for immunotherapy. , 2012, Immunotherapy.
[85] A. Hauschild,et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[86] K. Flaherty,et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[87] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[88] N. Moins,et al. Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [18F]ICF01006, a highly promising melanoma PET tracer , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[89] W. Su,et al. Quantification of Kryptofix 2.2.2 in [18F]fluorine-labelled radiopharmaceuticals by rapid-resolution liquid chromatography , 2012, Nuclear medicine communications.
[90] D. Cheresh,et al. αV integrins in angiogenesis and cancer. , 2011, Cold Spring Harbor perspectives in medicine.
[91] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[92] R. Hicks,et al. Improved Detection of Regional Melanoma Metastasis Using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-Specific PET Probe, by Perilesional Administration , 2011, The Journal of Nuclear Medicine.
[93] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[94] T. Poli,et al. Sentinel Node Biopsy in Head and Neck Squamous Cell Cancer: 5-Year Follow-Up of a European Multicenter Trial , 2010, Annals of Surgical Oncology.
[95] W. Mcbride,et al. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. , 2010, Bioconjugate chemistry.
[96] J. Fernandez-Miranda,et al. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. , 2010, Rhinology. Supplement.
[97] F. Saab,et al. Comparison of the efficiencies of two TR-FRET methods to detect in vitro natural and synthesized inhibitors of the Raf/MEK/ERK signaling pathway , 2010 .
[98] M. Pomper,et al. Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. , 2010, Cancer research.
[99] R. Hicks,et al. High-Contrast PET of Melanoma Using 18F-MEL050, a Selective Probe for Melanin with Predominantly Renal Clearance , 2010, Journal of Nuclear Medicine.
[100] J. Aguirre-Ghiso,et al. Dormancy of metastatic melanoma , 2010, Pigment cell & melanoma research.
[101] S. Gambhir,et al. Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[102] R. Hicks,et al. Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. , 2009, Journal of medicinal chemistry.
[103] A. Hauschild,et al. Staging of cutaneous melanoma , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[104] W. Mcbride,et al. A Novel Method of 18F Radiolabeling for PET , 2009, Journal of Nuclear Medicine.
[105] P. Garg,et al. Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors. , 2009, Bioconjugate chemistry.
[106] I. Greguric,et al. Synthesis and evaluation of novel radioiodinated nicotinamides for malignant melanoma. , 2008, Nuclear medicine and biology.
[107] Fan Wang,et al. Integrin αvβ3‐targeted cancer therapy , 2008 .
[108] I. Greguric,et al. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. , 2007, Journal of medicinal chemistry.
[109] Horst Kessler,et al. Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man , 2006, Clinical Cancer Research.
[110] M. Schwaiger,et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[111] A. Casadevall,et al. Melanin as a potential target for radionuclide therapy of metastatic melanoma. , 2005, Future oncology.
[112] Renato Marchesini,et al. Automated melanoma detection with a novel multispectral imaging system: results of a prospective study , 2005, Physics in medicine and biology.
[113] M. Gonen,et al. Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis , 2005, The American journal of surgical pathology.
[114] Horst Kessler,et al. Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.
[115] Wenjun Guo,et al. Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.
[116] J. Kirkwood,et al. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.
[117] M. A. Huber,et al. Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. , 2003, The Journal of investigative dermatology.
[118] A. Veyre,et al. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[119] W. Lehmann,et al. Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. , 2000, Journal of medicinal chemistry.
[120] G. Prota. Melanins, melanogenesis and melanocytes: looking at their functional significance from the chemist's viewpoint. , 2000, Pigment cell research.
[121] J. Lange,et al. Amelanotic melanoma: the great masquerader. , 2000, Journal of the American Academy of Dermatology.
[122] J. Park,et al. Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts* , 1999, The Journal of Biological Chemistry.
[123] D. Elder,et al. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. , 1998, The American journal of pathology.
[124] W. Holder,et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. , 1998, Annals of surgery.
[125] K. Dutschka,et al. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[126] D. Morton,et al. Prognostic factors in 1,521 melanoma patients with distant metastases. , 1995, Journal of the American College of Surgeons.
[127] K. Guan,et al. Dephosphorylation and inactivation of the mitogen-activated protein kinase by a mitogen-induced Thr/Tyr protein phosphatase. , 1993, The Journal of biological chemistry.
[128] A. Veyre,et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[129] J. Boire,et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[130] Erkki Ruoslahti,et al. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.
[131] K. Jimbow,et al. Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma. , 1984, Cancer research.
[132] M. Goldgeier,et al. The distribution of melanocytes in the leptomeninges of the human brain. , 1984, The Journal of investigative dermatology.
[133] Gams Ra,et al. Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). , 1974 .
[134] R. Lenhard,et al. Therapy of malignant melanoma with an imidazole carboxamide and bis‐chloroethyl nitrosourea , 1972, Cancer.
[135] J. Wolter,et al. Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma , 1971, Clinical pharmacology and therapeutics.
[136] Luce Jk,et al. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). , 1970 .
[137] Zhen Cheng,et al. PET Imaging of Melanoma Using Melanin-Targeted Probe. , 2021, Methods in molecular biology.
[138] C. Marquette,et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[139] Yongxue Zhang,et al. Imaging malignant melanoma with 18F-5-FPN , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[140] W. Ellis,et al. A Phase 2 study of 99mTc-trofolastat (MIP-1404) to identify prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection: an interim analysis , 2014 .
[141] W. Mcbride,et al. A Novel Method of 18 F Radiolabeling for PET , 2009 .
[142] Xiaoyuan Chen,et al. Integrin alpha(v)beta(3)-Targeted Cancer Therapy. , 2008, Drug development research.
[143] M. Schwaiger,et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[144] M. Schwaiger,et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. , 2004, Bioconjugate chemistry.
[145] A. Veyre,et al. [Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma]. , 2004, Journal francais d'ophtalmologie.
[146] M. Schwaiger,et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. , 2001, Cancer research.
[147] J C Briggs,et al. Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.
[148] J. Bernheim,et al. [Chemotherapy of melanoma]. , 1974, Acta chirurgica Belgica.
[149] W. G. Thurman,et al. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). , 1970, Cancer chemotherapy reports.